Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 5Ovarian Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Bladder Urothelial Carcinoma 1HRD Cancer 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Etoposide 3Cisplatin 3belinostat 2Topotecan 2veliparib 1cabozantinib 1berzosertib 1antineoplaston AS 2-1 1antineoplaston A10 1Sunitinib 1Specimen Handling 1Podophyllotoxin 1Platinum 1Nivolumab 1Melphalan 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Everolimus 1Complementary Therapies 1CTLA-4 Antigen 1Biopsy 1Biological Therapy 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Neuroendocrine × berzosertib × Clear all
NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
62 enrolled 29 charts
EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡